HMMC-1: a humanized monoclonal antibody with therapeutic potential against Müllerian duct-related carcinomas. 2004

Shiro Nozawa, and Daisuke Aoki, and Katsumi Tsukazaki, and Nobuyuki Susumu, and Motoko Sakayori, and Nao Suzuki, and Atsushi Suzuki, and Rie Wakita, and Makio Mukai, and Yuko Egami, and Kyoko Kojima-Aikawa, and Isao Ishida, and Frederic Belot, and Ole Hindsgaul, and Minoru Fukuda, and Michiko N Fukuda
Department of Obstetrics and Gynecology and Division of Diagnostic Pathology, School of Medicine, Keio University, Tokyo, Japan. shiron@sc.itc.keio.ac.jp

OBJECTIVE The purpose of this research was to generate a human monoclonal antibody specific to gynecological cancers and to evaluate such an antibody as therapy for gynecological cancers. METHODS Transchromosomal KM mice were immunized with the human uterine endometrial cancer cell line SNG-S. Hybridomas were constructed between spleen cells from KM mice and mouse myeloma cells. Reactivity of the antibody was evaluated by immunohistochemistry of pathological specimens of gynecological cancers. Cytotoxicity of HMMC-1 against SNG-S cells was tested by in vitro cytotoxicity assays. The epitope of HMMC-1 was determined by transfection with a panel of glycosyltransferase cDNAs and by inhibition assays with chemically synthesized oligosaccharides. RESULTS HMMC-1 is a human IgM monoclonal antibody that reacts positively with mullerian duct-related carcinomas with positive rates of 54.6% against uterine endometrial adenocarcinoma, 76.9% against uterine cervical adenocarcinoma, and 75.0% against epithelial ovarian cancer. HMMC-1 does not react with normal endometrium at proliferative or secretory phases, normal uterine cervix, or normal and malignant tissue from other organs, whereas it reacts weakly with the epithelium of the gall bladder and the collecting duct of the kidney. HMMC-1 exhibits antigen-dependent and complement-mediated cytotoxicity. Upon cotransfection with cDNAs encoding two glycosyltransferases required for fucosylated extended core 1 O-glycan, mammalian cells express HMMC-1 antigen. Finally, binding of HMMC-1 to SNG-S cells is inhibited by synthetic Fucalpha1-->2Galbeta1-->4GlcNAcbeta1-->3Galbeta1-->3GalNAcalpha1-octyl. CONCLUSIONS These results indicate that HMMC-1 specifically recognizes a novel O-glycan structure. The unique specificity and cytotoxicity of HMMC-1 strongly suggest a therapeutic potential of this antibody.

UI MeSH Term Description Entries
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D009095 Mullerian Ducts A pair of ducts near the WOLFFIAN DUCTS in a developing embryo. In the male embryo, they degenerate with the appearance of testicular ANTI-MULLERIAN HORMONE. In the absence of anti-mullerian hormone, mullerian ducts give rise to the female reproductive tract, including the OVIDUCTS; UTERUS; CERVIX; and VAGINA. Muellerian Duct,Mullerian Duct,Muellerian Ducts,Duct, Muellerian,Duct, Mullerian,Ducts, Muellerian,Ducts, Mullerian
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D005260 Female Females
D005833 Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE). Gynecologic Neoplasms,Female Genital Neoplasms,Neoplasms, Female Genital,Neoplasms, Gynecologic,Female Genital Neoplasm,Genital Neoplasm, Female,Gynecologic Neoplasm,Neoplasm, Female Genital,Neoplasm, Gynecologic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006825 Hybridomas Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell. Hybridoma
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Shiro Nozawa, and Daisuke Aoki, and Katsumi Tsukazaki, and Nobuyuki Susumu, and Motoko Sakayori, and Nao Suzuki, and Atsushi Suzuki, and Rie Wakita, and Makio Mukai, and Yuko Egami, and Kyoko Kojima-Aikawa, and Isao Ishida, and Frederic Belot, and Ole Hindsgaul, and Minoru Fukuda, and Michiko N Fukuda
May 2005, Nature medicine,
Shiro Nozawa, and Daisuke Aoki, and Katsumi Tsukazaki, and Nobuyuki Susumu, and Motoko Sakayori, and Nao Suzuki, and Atsushi Suzuki, and Rie Wakita, and Makio Mukai, and Yuko Egami, and Kyoko Kojima-Aikawa, and Isao Ishida, and Frederic Belot, and Ole Hindsgaul, and Minoru Fukuda, and Michiko N Fukuda
January 2021, Frontiers in immunology,
Shiro Nozawa, and Daisuke Aoki, and Katsumi Tsukazaki, and Nobuyuki Susumu, and Motoko Sakayori, and Nao Suzuki, and Atsushi Suzuki, and Rie Wakita, and Makio Mukai, and Yuko Egami, and Kyoko Kojima-Aikawa, and Isao Ishida, and Frederic Belot, and Ole Hindsgaul, and Minoru Fukuda, and Michiko N Fukuda
January 1982, Endocrinology,
Shiro Nozawa, and Daisuke Aoki, and Katsumi Tsukazaki, and Nobuyuki Susumu, and Motoko Sakayori, and Nao Suzuki, and Atsushi Suzuki, and Rie Wakita, and Makio Mukai, and Yuko Egami, and Kyoko Kojima-Aikawa, and Isao Ishida, and Frederic Belot, and Ole Hindsgaul, and Minoru Fukuda, and Michiko N Fukuda
June 2022, Acta crystallographica. Section D, Structural biology,
Shiro Nozawa, and Daisuke Aoki, and Katsumi Tsukazaki, and Nobuyuki Susumu, and Motoko Sakayori, and Nao Suzuki, and Atsushi Suzuki, and Rie Wakita, and Makio Mukai, and Yuko Egami, and Kyoko Kojima-Aikawa, and Isao Ishida, and Frederic Belot, and Ole Hindsgaul, and Minoru Fukuda, and Michiko N Fukuda
May 2009, Protein engineering, design & selection : PEDS,
Shiro Nozawa, and Daisuke Aoki, and Katsumi Tsukazaki, and Nobuyuki Susumu, and Motoko Sakayori, and Nao Suzuki, and Atsushi Suzuki, and Rie Wakita, and Makio Mukai, and Yuko Egami, and Kyoko Kojima-Aikawa, and Isao Ishida, and Frederic Belot, and Ole Hindsgaul, and Minoru Fukuda, and Michiko N Fukuda
January 2012, PLoS neglected tropical diseases,
Shiro Nozawa, and Daisuke Aoki, and Katsumi Tsukazaki, and Nobuyuki Susumu, and Motoko Sakayori, and Nao Suzuki, and Atsushi Suzuki, and Rie Wakita, and Makio Mukai, and Yuko Egami, and Kyoko Kojima-Aikawa, and Isao Ishida, and Frederic Belot, and Ole Hindsgaul, and Minoru Fukuda, and Michiko N Fukuda
October 1988, American journal of reproductive immunology and microbiology : AJRIM,
Shiro Nozawa, and Daisuke Aoki, and Katsumi Tsukazaki, and Nobuyuki Susumu, and Motoko Sakayori, and Nao Suzuki, and Atsushi Suzuki, and Rie Wakita, and Makio Mukai, and Yuko Egami, and Kyoko Kojima-Aikawa, and Isao Ishida, and Frederic Belot, and Ole Hindsgaul, and Minoru Fukuda, and Michiko N Fukuda
March 2023, Antimicrobial agents and chemotherapy,
Shiro Nozawa, and Daisuke Aoki, and Katsumi Tsukazaki, and Nobuyuki Susumu, and Motoko Sakayori, and Nao Suzuki, and Atsushi Suzuki, and Rie Wakita, and Makio Mukai, and Yuko Egami, and Kyoko Kojima-Aikawa, and Isao Ishida, and Frederic Belot, and Ole Hindsgaul, and Minoru Fukuda, and Michiko N Fukuda
January 2016, mAbs,
Shiro Nozawa, and Daisuke Aoki, and Katsumi Tsukazaki, and Nobuyuki Susumu, and Motoko Sakayori, and Nao Suzuki, and Atsushi Suzuki, and Rie Wakita, and Makio Mukai, and Yuko Egami, and Kyoko Kojima-Aikawa, and Isao Ishida, and Frederic Belot, and Ole Hindsgaul, and Minoru Fukuda, and Michiko N Fukuda
March 2024, PLoS neglected tropical diseases,
Copied contents to your clipboard!